Histotripsy for liver tumors: What HOPE4LIVER Found

Histotripsy for liver tumors can destroy a selected volume of tissue through intact skin, without inserting a needle into the tumor, using ionizing radiation, or heating the lesion. In the HOPE4LIVER trial, physicians identified the target with ultrasound while a robotic system moved the focus of powerful acoustic pulses through a predefined treatment volume.

A year later, an unexpected issue became apparent. Blood vessels can remain intact within tissue disrupted by histotripsy. On follow-up imaging, an enhancing vessel may resemble surviving tumor, meaning that imaging rules developed for other forms of ablation do not always translate cleanly to this new technique.

How sound mechanically breaks down tissue

Histotripsy is a form of local tissue ablation, but its physical mechanism differs from most established techniques. Radiofrequency and microwave ablation heat tissue. Cryoablation freezes it. Histotripsy primarily destroys tissue mechanically.

Extremely short, focused ultrasound pulses generate large pressure changes at the focal point. This produces a cloud of microscopic bubbles through a process known as cavitation. The bubbles rapidly form, expand, and collapse, mechanically disrupting cellular structures. By moving the focal point throughout a prescribed volume, the system breaks down and partially liquefies the targeted tissue.

In HOPE4LIVER, the bubble cloud and treatment area could be monitored with diagnostic ultrasound while a robotic arm moved the therapeutic focus through the target.

Noninvasive, however, does not mean trivial. All 47 patients underwent general anesthesia, and the median total procedure time was 201 minutes — more than three hours.

The study included 19 patients with hepatocellular carcinoma and 28 with metastatic liver disease. Fifty-two tumors were treated. The median target diameter was only 1.3 cm, and the protocol allowed treatment of no more than three target tumors smaller than 3 cm.

Most participants nevertheless had substantially greater disease burden. Multifocal liver disease was present in 17 of 19 patients with hepatocellular carcinoma and 27 of 28 patients with metastatic disease. Participants were unable to undergo standard treatments, had failed or could not tolerate previous therapies, or had declined standard options.

On early CT or MRI, complete coverage by the histotripsy treatment zone was confirmed in 45 of 47 tumors that could be assessed for this outcome.

Why the same study reports 63.4% and 90%

At one year, local tumor control was calculated in two different ways. The primary imaging assessment produced an estimated freedom from local progression of 63.4%. A later post hoc review, incorporating experience gained in interpreting post-histotripsy imaging, produced an estimate of 90%.

The reason for the discrepancy is closely connected to the physics of the treatment.

Histotripsy can disrupt soft tissue while leaving some structurally resilient tissue intact. A functioning blood vessel may therefore remain within the treatment zone. After contrast administration, that vessel enhances on CT or MRI. With conventional ablation criteria, enhancement within a treated region can raise suspicion that viable tumor remains.

The study describes an example in which enhancement was initially classified as progression but was later recognized as an intact vessel within the treated region.

That distinction matters. The widely cited 90% figure is a post hoc result and should not be treated as if it were an uncomplicated, prespecified measure of efficacy. At the same time, the disagreement between the two assessments highlights a genuine challenge: a therapy with a different mechanism can require different rules for interpreting what successful treatment looks like on imaging.

The treated regions also tended to shrink substantially over time. Among 22 tumors in which treatment-zone involution could be assessed at one year, 18 showed a reduction in volume. In those tumors, the median volume reduction was 96.4%.

What HOPE4LIVER cannot yet establish

HOPE4LIVER was a prospective, multicenter study, but it was nonrandomized and had no control group. It therefore cannot establish that histotripsy is superior to surgery, radiation therapy, or established forms of ablation.

The survival data should be interpreted with the same caution. One-year overall survival was 73.3% among patients with hepatocellular carcinoma and 48.6% among those with metastatic disease. The patient groups were small and heterogeneous, many had extensive disease and previous treatment, and there was no randomized comparator. These percentages cannot demonstrate that histotripsy prolonged survival.

By the 12-month visit, 27 of the original 47 patients remained in active follow-up. That attrition is particularly relevant when interpreting longer-term estimates of local control.

Histotripsy was also not free of serious complications. Six serious device-related adverse effects occurred within the first 30 days, including hepatic failure, thrombosis, sepsis, and severe procedural pain. One patient with a high burden of liver metastases later died following hepatic failure classified as device-related.

The trial also did not test treatment directly involving several critical structures. Patients were excluded when the planned treatment volume included the main portal vein, common hepatic duct, common bile duct, gallbladder, stomach, or bowel.

Histotripsy therefore should not be understood as a way to “destroy cancer with sound” throughout the body. It is a local treatment for a selected and technically accessible target.

What is already clear is narrower, but still important: focused ultrasound can mechanically destroy targeted tumor tissue inside the liver without an incision, puncture, or thermal ablation. The next question is no longer whether the physical method works. It is which patients benefit most from it, how durable that benefit is, and how histotripsy compares directly with existing treatment options.